HomeCompareNVTA vs VIG

NVTA vs VIG: Dividend Comparison 2026

NVTA yields 10526.32% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVTA wins by $91421458538285344.00M in total portfolio value
10 years
NVTA
NVTA
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full NVTA calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — NVTA vs VIG

📍 NVTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVTAVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVTA + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVTA pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVTA
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, NVTA beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVTA + VIG for your $10,000?

NVTA: 50%VIG: 50%
100% VIG50/50100% NVTA
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VIG right now

NVTA
Analyst Ratings
4
Buy
6
Hold
5
Sell
Consensus: Hold
Price Target
$9.75
+51215.8% upside vs current
Range: $2.25 — $17.00
Altman Z
-23.1
Piotroski
4/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVTA buys
0
VIG buys
0
No recent congressional trades found for NVTA or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVTAVIG
Forward yield10526.32%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$91421458538285344.00M$32.4K
Annual income after 10y$89,744,322,218,307,970,000,000.00$179.15
Total dividends collected$91309952364754128.00M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NVTA vs VIG ($10,000, DRIP)

YearNVTA PortfolioNVTA Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$1,063,332$1,052,631.58$11,304$163.92+$1.05MNVTA
2$105,744,905$104,607,140.08$12,759$166.33+$105.73MNVTA
3$9,835,430,757$9,722,283,708.79$14,382$168.52+$9835.42MNVTA
4$855,644,041,989$845,120,131,078.84$16,192$170.52+$855644.03MNVTA
5$69,627,827,846,009$68,712,288,721,080.95$18,210$172.34+$69627827.83MNVTA
6$5,300,152,192,813,391$5,225,650,417,018,161.00$20,460$173.98+$5300152192.79MNVTA
7$377,430,657,448,967,200$371,759,494,602,656,830.00$22,968$175.48+$377430657448.94MNVTA
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$25,763$176.83+$25145413383015.19MNVTA
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$28,878$178.05+$1567417121474185.50MNVTA
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$32,350$179.15+$91421458538285344.00MNVTA

NVTA vs VIG: Complete Analysis 2026

NVTAStock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Full NVTA Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this NVTA vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVTA vs SCHDNVTA vs JEPINVTA vs ONVTA vs KONVTA vs MAINNVTA vs DGRONVTA vs NOBLNVTA vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.